Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof

Inventors

Friedman, Milton J. • Kauvar, Lawrence M.

Assignees

Trellis Bioscience Inc

Abstract

Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.

Core Innovation

The invention provides an immunogen against respiratory syncytial virus (RSV) that comprises a complex formed by an RSV G protein or peptidomimetic. The RSV G protein includes a central conserved domain (CCD), and the CCD is associated with a monoclonal antibody or an antigen-binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1.

The invention further defines the RSV G target in terms of CCD residue regions, including residues 131-230 and/or residues 167-176. The associated monoclonal antibody or antigen-binding fragment has affinity characterized by a Kd of less than about 1 nM, and the immunogen is structured as a specific RSV G CCD–antibody complex intended to provide an extended protective lifetime against RSV.

The document context also describes inhalation use of the immunogen and related immunogen/vaccine compositions. It further describes Fc engineering of the monoclonal antibody, including FcRn binding and/or mucin binding, and Fc modifications such as a YTE mutation, to support extended protective lifetime and RSV prophylaxis/treatment while addressing adverse CX3C-mediated effects linked to CX3CR1 interaction.

Claims Coverage

The partial content includes two independent claims. Across these claims, the inventive features focus on an RSV G CCD–monoclonal antibody complex that blocks recombinant RSV G interaction with host receptor CX3CR1, together with defined CCD residue regions, high-affinity binding, inhalation, and extended protective lifetime via Fc-related features.

Together, the independent claims cover immunogen complexes built around the RSV G central conserved domain (CCD) paired with a monoclonal antibody or antigen-binding fragment that blocks RSV G interaction with the host receptor CX3CR1. The claim coverage further narrows the RSV G CCD to residues 131-230 and/or 167-176, requires high-affinity antibody binding with Kd less than about 1 nM, and includes inhalation as an intended format in the second independent claim.

Stated Advantages

Documented Applications